These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 26979735)
1. Inhibition of Glycogen Synthase Kinase-3: An Emerging Target in the Treatment of Traumatic Brain Injury. Shim SS; Stutzmann GE J Neurotrauma; 2016 Dec; 33(23):2065-2076. PubMed ID: 26979735 [TBL] [Abstract][Full Text] [Related]
2. A new avenue for lithium: intervention in traumatic brain injury. Leeds PR; Yu F; Wang Z; Chiu CT; Zhang Y; Leng Y; Linares GR; Chuang DM ACS Chem Neurosci; 2014 Jun; 5(6):422-33. PubMed ID: 24697257 [TBL] [Abstract][Full Text] [Related]
3. Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death. Lin CJ; Chen TH; Yang LY; Shih CM Cell Death Dis; 2014 Mar; 5(3):e1147. PubMed ID: 24675465 [TBL] [Abstract][Full Text] [Related]
4. Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. Dash PK; Johnson D; Clark J; Orsi SA; Zhang M; Zhao J; Grill RJ; Moore AN; Pati S PLoS One; 2011; 6(9):e24648. PubMed ID: 21935433 [TBL] [Abstract][Full Text] [Related]
5. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease. Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329 [TBL] [Abstract][Full Text] [Related]
6. Lithium, a potential protective drug in Alzheimer's disease. Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of breviscapine on traumatic brain injury in rats associated with the inhibition of GSK3β signaling pathway. Jiang L; Xia QJ; Dong XJ; Hu Y; Chen ZW; Chen K; Wang KH; Liu J; Wang TH Brain Res; 2017 Apr; 1660():1-9. PubMed ID: 28143715 [TBL] [Abstract][Full Text] [Related]
8. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Huang HC; Klein PS Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579 [TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3beta activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. Lee KY; Koh SH; Noh MY; Park KW; Lee YJ; Kim SH Brain Res; 2007 Jan; 1129(1):89-99. PubMed ID: 17157278 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. Noh MY; Koh SH; Kim Y; Kim HY; Cho GW; Kim SH J Neurochem; 2009 Mar; 108(5):1116-25. PubMed ID: 19077054 [TBL] [Abstract][Full Text] [Related]
11. Curcumin-mediated neuroprotection against amyloid-β-induced mitochondrial dysfunction involves the inhibition of GSK-3β. Huang HC; Xu K; Jiang ZF J Alzheimers Dis; 2012; 32(4):981-96. PubMed ID: 22886017 [TBL] [Abstract][Full Text] [Related]
15. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Simão F; Matté A; Pagnussat AS; Netto CA; Salbego CG Eur J Neurosci; 2012 Oct; 36(7):2899-905. PubMed ID: 22817531 [TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335 [TBL] [Abstract][Full Text] [Related]
17. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Avila J; Wandosell F; Hernández F Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491 [TBL] [Abstract][Full Text] [Related]
18. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Koh SH; Noh MY; Kim SH Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715 [TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837 [TBL] [Abstract][Full Text] [Related]
20. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]